Autoimmune (AI) diseases occur when a person’s immune system makes an inappropriate response, attacking healthy organs and tissues. Immunosuppressants are the most common form of treatment, but often fail to adequately manage the disease.
There is growing optimism that using targeted therapies can “re-program” the immune system of those with AI, so it’s important for researchers to learn how this development can lead to long-term success in managing these diseases.
Join us to learn how combining disease-relevant models and in vitro assays can provide a clear picture for your therapy to reprogram the immune system, resulting in a more efficient approach to efficacy studies.
Louise Brackenbury, PhD
Group Leader (Cell Biology) Discovery Services
Paolo Campoli, PhD
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.
During this time of uncertainty, we are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.